Baxter announces US launch of premix drug Vancomycin injection in sodium chloride

Only manufacturer to offer the antibiotic in a ready-to-use premixed presentation.

Baxter is the only manufacturer to offer Vancomycin in a premixed presentation, which uses the company’s proprietary frozen GALAXY container technology. Baxter’s innovative frozen premix technology is specifically designed for unstable molecules that are often administered using standardized doses. Premixed molecules offered in the GALAXY container are illustrative of the leading innovation in medical manufacturing that Baxter has been bringing to the healthcare industry for more than 80 years.

Vancomycin saline injection augments Baxter’s expanding portfolio of generic injectable drugs in the United States available in easy-to-use presentations that hospitals, physicians and patients can rely on because they are manufactured to the Current Good Manufacturing Practice (cGMP) regulations established by the FDA. Premixed medications in standardized drug concentrations can help support hospitals’ goals for safe and efficient medication preparation because compounding is not necessary.

''As a company whose mission is focused on saving and sustaining lives, Baxter’s launch of Vancomycin injection in an innovative premixed saline presentation provides new options of an important antibiotic to address patient needs and demonstrates our commitment to making premixed preparations of medications more efficient for healthcare practitioners,'' said Brik Eyre, president of Baxter’s Hospital Products business.

The launch is an extension of Baxter’s existing Vancomycin injection in 5% dextrose in 500 mg, 750 mg and 1 gram presentations and provides an alternative to certain patients who may need to avoid receiving additional dextrose. By providing Vancomycin in both saline and dextrose presentations, Baxter makes additional therapy options available of a critical antibiotic that has appeared on and off of the FDA Drug Shortage list.

Vancomycin saline injection is the second of nine clinically important molecules coming out of a collaborative partnership with Celerity Pharmaceuticals, a company of Water Street Healthcare Partners, to develop new products that use Baxter’s proprietary container technology, enhanced packaging platform, and aseptic filling manufacturing process.

Baxter’s Vancomycin saline injection in 500 mg, 750 mg and 1 gram presentations are available in the US.